All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-000478-30 | A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of bosentan in patients with mildly symptomatic pulmonary arterial hypertension. S... | 2011-02-11 | due-trials |
| Completed, but no date, and reported results | 2004-000631-28 | Bosentan use in interstitial lung disease (open label). Long-term open-label study in patients with interstitial lung disease associated with systemic sclerosis who completed the protocol AC-052-330/B... | bad-data | |
| Reported results | 2004-000632-82 | Long term bosentan open label extension of the RAPIDS-2 study in Systemic Sclerosis patients with ischemic digital ulcers | 2009-01-26 | due-trials |
| Reported results | 2004-000745-37 | Uncontrolled extension trial to protocol AC-052-406 to evaluate the long term effect of bosentan therapy in patient with pulmonary arterial hypertension related to connective tissue disease (TRUST-ext... | 2006-09-28 | due-trials |
| Reported results | 2004-002453-31 | A Phase IIb, multi-center, international, double-blind, randomized, placebo-controlled, parallel-group, dose-finding study for the prevention of cerebral vasospasm after aneurysmal subarachnoid hemorr... | 2006-03-20 | due-trials |
| Reported results | 2004-004391-36 | A multicenter, open-label, single-arm safety study to investigate the effects of chronic TRACLEER® treatment on testicular function in male patients with pulmonary arterial hypertension | 2007-02-21 | due-trials |
| Reported results | 2004-005157-63 | An open label multicenter study to assess the pharmacokinetic, tolerability and safety of a pediatric formulation of bosentan in children with idiopathic or familial pulmonary arterial hypertension i... | 2006-02-09 | due-trials |
| Reported results | 2005-001651-37 | A phase IV, open label, non comparative, multicenter study to evaluate the long term efficacy and safety and tolerability of oral miglustat as a maintenance after a switch form enzyme replacement ther... | 2010-06-22 | due-trials |
| Reported results | 2005-001965-33 | Estudio prospectivo, aleatorizado, controlado con placebo, doble-ciego, multicéntrico, en grupos paralelos, para evaluar la eficacia, seguridad y tolerabilidad de bosentan en pacientes con hipertensió... | 2007-02-07 | due-trials |
| Reported results | 2005-001967-70 | An open label long term safety and tolerability extension study using the pediatric formulation of bosentan in the treatment of children with idiopathic or familial pulmonary arterial hypertension who... | 2011-10-28 | due-trials |
| Reported results | 2005-002900-40 | BENEFIT-OL / Estudio abierto de extensión a largo plazo en pacientes con hipertensión pulmonar tromboembólica crónica (HPTC) inoperable que hayan completado el protocolo AC-052-366/BENEFIT | 2009-02-23 | due-trials |
| Reported results | 2005-005066-37 | COMPASS-1 / Hemodynamic effects of a single dose of sildenafil in symptomatic patients on bosentan treatment for pulmonary arterial hypertension – A multicenter, open-label, non-comparative, prospecti... | 2006-11-30 | due-trials |
| Reported results | 2005-005068-97 | Effects of combination of bosentan and sildenafil versus sildenafil monotherapy on morbidity and mortality in symptomatic patients with pulmonary arterial hypertension – A multicenter, double - blind,... | 2013-12-06 | due-trials |
| Reported results | 2005-006192-13 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ADDITION OF INHALED ILOPROST IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) RECEIVING ORAL SILDE... | 2008-07-17 | due-trials |
| Reported results | 2006-000374-75 | Long-term, open-label, multicenter extension study of bosentan in patients with pulmonary hypertension associated with sickle cell disease completing a double-blind ASSET study (AC-052-368 or AC-052-3... | 2020-08-28 | due-trials |
| Reported results | 2006-001183-24 | Efectos de Bosentan sobre la morbilidad y mortalidad en pacientes con Fibrosis Pulmonar Idiopática- Estudio fase III, multicéntrico, randomizado, de grupos paralelos, doble ciego, controlado con plac... | 2010-04-29 | due-trials |
| Reported results | 2006-002049-35 | "Estudio unicéntrico, a doble ciego, aleatorizado y controlado con placebo, cruzado de 2 brazos, para investigar el efecto de miglustat sobre la diferencia de potencial nasal en pacientes con fibrosi... | 2008-02-22 | due-trials |
| Reported results | 2006-002907-15 | Multicenter, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of tezosentan in patients with pre-operative pulmonary hypertension, due... | 2008-05-06 | due-trials |
| Reported results | 2007-001741-18 | Estudio de extensión abierta en pacientes con Fibrosis Pulmonar Idiopática que hayan completado el protocolo AC-052-321 / BUILD 3 | 2010-04-16 | due-trials |
| Reported results | 2007-002440-14 | A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel group, Event driven, Phase III study to assess the effects of ACT-064992 on Morbidity and Mortality in patients with Symptomatic P... | 2012-03-15 | due-trials |
| Reported results | 2007-002584-27 | A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-cause m... | 2010-08-02 | due-trials |
| Reported results | 2007-003328-39 | A multi-centre, multinational, open-label single-dose acute hemodynamic study followed by a multi-centre, multinational, randomized, double-blind, parallel-group, placebo controlled study to assess ... | 2009-06-23 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2007-003694-27 | Long-term, single-arm, open label extension study of the SERAPHIN study to assess the safety and tolerability of ACT 064992 in patients with symptomatic pulmonary arterial hypertension. | 2020-12-07 | bad-data |
| Reported results | 2007-005194-56 | Estudio multicéntrico de polisomnografía, aleatorizado, a doble ciego y controlado con placebo, de grupos paralelos, con grupo de referencia con tratamiento activo, para evaluar la eficacia y la segu... | 2009-10-16 | due-trials |
| Reported results | 2007-006453-12 | A multi-centre, multinational, open- label study to evaluate the long-term safety, tolerability and efficacy of ACT-293987 (NS-304) in the treatment of pulmonary arterial hypertension in subjects aged... | 2017-12-19 | due-trials |
| Reported results | 2008-001209-41 | A multi-center, double-blind, placebo-controlled, randomized, multiple dose, 2-period cross-over, Phase IIa study to investigate the pharmacodynamics, tolerability and safety, and pharmacokinetics of ... | 2009-01-15 | due-trials |
| Reported results | 2008-001443-19 | Multicenter, randomized, double-blind, placebo-controlled, Phase IIa study to evaluate the efficacy, safety, and tolerability of ACT-128800, an S1P1 receptor agonist, administered for 6 weeks to subje... | 2020-07-31 | due-trials |
| Completed, but no date, and reported results | 2008-002352-20 | Single center, double-blind, randomized, placebo-controlled, two-period/two-treatment crossover study investigating the effect of miglustat on the nasal potential difference in patients with cystic fi... | bad-data | |
| Reported results | 2008-006054-17 | A double-blind, randomized, placebo-controlled, multicenter, parallel group study to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis | 2011-06-30 | due-trials |
| Reported results | 2008-006785-29 | A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-cause ... | 2011-01-26 | due-trials |
| Reported results | 2008-006786-92 | Estudio multicéntrico, aleatorizado, de grupos paralelos, doble ciego, controlado con placebo, de búsqueda de dosis para evaluar la eficacia, seguridad y tolerabilidad de tres dosis de ACT-128800, un ... | 2011-06-17 | due-trials |
| Reported results | 2008-007653-12 | Determination of ( 11 C) miglustat uptake in bone tissue and brain using Positron Emission Tomography (PET). | 2009-10-06 | due-trials |
| Reported results | 2009-010703-80 | A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients with Symptomatic Pulmonary Ar... | 2009-08-31 | due-trials |
| Completed, but no date, and reported results | 2009-011013-24 | A Multicenter, Double-blind, Randomized Study comparing the Safety and Tolerability of Iloprost inhalation solution delivered by I-neb utilizing Power disc-15 and Power disc-6 in Patients with Symptom... | bad-data | |
| Listed as ongoing, but also has a completion date | 2009-011470-15 | Estudio de extensión del estudio AC-058B201, multicéntrico, aleatorizado, de grupos paralelos, doble ciego, para evaluar la seguridad, tolerabilidad, y eficacia a largo plazo de 10, 20, y 40 mg/día ... | 2023-09-06 | bad-data |
| Reported results | 2009-011975-60 | A multi-center, double-blind, placebo-controlled, parallel-group study to establish proof-of-concept and explore the efficacy of different doses of ACT-129968 in adult patients with partly controlled ... | 2012-01-12 | due-trials |
| Reported results | 2009-012450-20 | Multicenter, open-label, non-comparative, proof-of-concept, phase 2a study to evaluate the effect of a single infusion of tezosentan on pulmonary vascular resistance in patients with stable, chronic p... | 2011-05-10 | due-trials |
| Reported results | 2009-014490-41 | A multicenter, double-blind, placebo-controlled Phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary arterial hypertension Studio multicentrico, in doppio... | 2014-04-27 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2009-014992-31 | Estudio de extensión abierta, de grupo único de tratamiento y a largo plazo, para evaluar la seguridad y tolerabilidad de ACT-293987 en pacientes con hipertensión arterial pulmonar | 2021-09-29 | bad-data |
| Ongoing | 2009-015602-18 | Diabetes and vascular complications: the role of endothelin and physical inactivity’ | not-yet-due | |
| Reported results | 2010-018320-10 | An open-label extension of study AC-066A301 investigating the safety and tolerability of ACT-385781A in patients with pulmonary arterial hypertension (PAH) | 2015-06-24 | due-trials |
| Reported results | 2010-018322-40 | A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to ACT-385781A in Patients with Pulmonary Arterial Hypertension | 2012-02-02 | due-trials |
| Reported results | 2010-019283-36 | A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of two doses of ACT-128800, an oral S1P1 receptor agonist, administe... | 2012-10-24 | due-trials |
| Reported results Terminated | 2010-020941-29 | A multi-center, double-blind, randomized, active reference, parallel group study to evaluate the efficacy, safety and tolerability of a 10-day twice daily oral administration of 3 doses of ACT-179811 ... | 2012-11-12 | due-trials |
| Trial is partly outside EEC, and reported results | 2010-021793-12 | A prospective, multicenter, open-label extension of FUTURE 3 to assess the safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with pul... | 2014-08-13 | bad-data |
| Trial is partly outside EEC, and reported results | 2010-021825-11 | An open label, prospective multicenter study to assess the pharmacokinetics, tolerability, safety and efficacy of the pediatric formulation of bosentan two versus three times a day in children with pu... | 2013-08-26 | bad-data |
| Reported results | 2010-022710-77 | Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of macitentan in patients with ischemic digital ulcers as... | 2013-11-29 | due-trials |
| Reported results | 2010-022969-95 | Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of macitentan in patients with ischemic digital ulcers asso... | 2014-02-06 | due-trials |
| Reported results | 2010-023908-27 | Effects of bosentan in a HOMogenEous population of SSc subjects with a predefined restriction of blood flow in the hands (HOME) | 2012-11-28 | due-trials |
| Reported results | 2010-024211-13 | Long term, single-arm, open-label extension study of the MUSIC study to assess the safety and tolerability of macitentan in patients with idiopathic pulmonary fibrosis | 2012-02-17 | due-trials |
| Trial is partly outside EEC, and reported results | 2011-000203-41 | Multicenter, double-blind, placebo-controlled, randomized, prospective study of bosentan as adjunctive therapy to inhaled nitric oxide in the management of persistent pulmonary hypertension of the new... | 2014-01-27 | bad-data |
| Reported results | 2011-003310-17 | "Estudio fase II, multicentrico, doble ciego, randomizado, controlado con placebo para evaluar los efectos de IIoprost inhalado en una prueba de resistencia durante un test de ejercicio cardiopulmonar... | 2012-11-30 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2011-004106-16 | A randomized, prospective, double-blind, placebo-controlled, group sequential multicenter study to assess efficacy, safety, and tolerability of the pediatric formulation of bosentan in children with p... | 2012-06-01 | bad-data |
| Ongoing, reported early | 2011-004612-31 | A prospective, multicenter, non-comparative, open label extension of the FUTURE 5 study to assess safety and tolerability of the pediatric formulation of bosentan in children with pulmonary arterial h... | not-yet-due | |
| Reported results | 2011-005303-32 | Effects of bosentan in a HOMogenEous population of SSc subjects with an early or active SSc nailfold capillaroscopic pattern (HOME II) Effecten van bosentan in een homogene populatie van sclerode... | 2014-06-03 | due-trials |
| Reported results | 2012-000540-10 | Multicenter, randomized, double-blind, parallel-group, active-controlled, superiority study to compare the efficacy and safety of ponesimod to teriflunomide in subjects with relapsing multiple scleros... | 2019-05-16 | due-trials |
| Reported results | 2012-000541-12 | Multicenter, randomized, double-blind, parallel-group, add-on, superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are... | 2020-03-26 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2012-001829-27 | Multi-center non-drug-interventional extension study to assess long-term safety and effects on growth in patients who received bosentan or placebo as adjunctive therapy to inhaled nitric oxide for per... | 2014-12-05 | bad-data |
| Reported results | 2012-003335-33 | A multi-center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study to evaluate the effects of macitentan on exercise capacity in subjects with Eisenmenger Syndrome. Studi... | 2016-12-01 | due-trials |
| Reported results | 2012-004411-31 | Long term, single-arm, open-label extension study of protocol AC-055-305 to assess the safety, tolerability and efficacy of macitentan in subjects with Eisenmenger Syndrome | 2018-01-12 | due-trials |
| Reported results | 2013-002508-15 | A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD) | 2017-06-02 | due-trials |
| Reported results | 2013-002528-17 | A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD) | 2017-03-24 | due-trials |
| Reported results | 2013-002950-56 | Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel-group, 24-week study to assess the efficacy, safety and tolerability of macitentan in subjects with inoperable chronic ... | 2016-09-28 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-003457-25 | Long term, multicenter, single-arm, open-label extension study of the MERIT-1 study, to assess the safety, tolerability and efficacy of macitentan in subjects with inoperable chronic thromboembolic pu... | 2022-03-21 | bad-data |
| Reported results | 2013-003462-14 | A multi-center, open-label, single-arm, Phase 3b study of macitentan in patients with pulmonary arterial hypertension to psychometrically validate the French, Italian and Spanish versions of the PAH-S... | 2015-09-09 | due-trials |
| Reported results | 2013-003489-15 | An extension of AC-055-310, a multi-center, open-label, single-arm, Phase 3b study of macitentan in patients with pulmonary arterial hypertension to psychometrically validate the French, Italian and S... | 2018-09-17 | due-trials |
| Reported results | 2013-003822-96 | A prospective, multicenter, double-blind, randomized, placebo-controlled, parallel group, 12-week study to evaluate the safety and tolerability of macitentan in subjects with combined pre- and post-ca... | 2015-11-15 | due-trials |
| Reported results | 2014-000865-34 | A multi-center, double-blind, randomized, placebo-controlled, parallel group, exploratory Phase 2 study to assess efficacy and safety of selexipag in adult subjects with Raynaud's Phenomenon secondary... | 2015-06-07 | due-trials |
| Reported results | 2014-002984-14 | A multicenter, randomized, double-blind, placebo-controlled, dose-response study to investigate the biological activity, safety, tolerability, and pharmacokinetics of ACT-334441 in subjects with syste... | 2017-02-28 | due-trials |
| Reported results | 2014-004066-20 | A prospective, multicenter, single-arm, open-label, phase 4 study to evaluate the effects of macitentan on Right vEntricular remodeling in Pulmonary ArterIal hypeRtension assessed by cardiac magnetic ... | 2019-08-25 | due-trials |
| Reported results | 2014-004624-21 | A randomized, double-blind, placebo-controlled, prospective, multicenter, parallel group study to assess the safety and efficacy of macitentan in patients with portopulmonary hypertension | 2018-10-31 | due-trials |
| Ongoing | 2014-004786-25 | Prospective, multi-center, double-blind, randomized, active-controlled, triple-dummy, parallel-group, group-sequential, adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan... | not-yet-due | |
| Reported results | 2015-002078-19 | Prospective, multicenter, open-label study evaluating the effects of first-line oral combination therapy of macitentan and tadalafil in patients with newly diagnosed pulmonary arterial hypertension. ... | 2018-09-10 | due-trials |
| Completed, but no date, and reported results Terminated | 2015-002721-18 | A prospective, multi-center, open-label, single-arm, Phase 2 study to assess the efficacy and safety of clazosentan in reversing angiographically-confirmed cerebral vasospasm in adult subjects with an... | bad-data | |
| Reported results | 2015-003438-28 | The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebo-controlle... | 2020-05-05 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-004805-17 | A prospective, multicenter study to investigate the pharmacokinetics, safety, and efficacy of cadazolid versus vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea. | 2018-04-17 | bad-data |
| Reported results | 2016-000826-21 | Multi-center, double-blind, randomized, placebo-controlled, active reference, parallel-group, polysomnography dose response study to assess the efficacy and safety of ACT-541468 in adult subjects with... | 2017-06-20 | due-trials |
| Reported results | 2016-000827-16 | Multi-center, double-blind, randomized, placebo-controlled, 5-period, 5-treatment crossover, polysomnography dose-response study to assess the efficacy and safety of ACT-541468 in elderly subjects wit... | 2017-06-29 | due-trials |
| Trial is partly outside EEC | 2016-001062-28 | A multicenter, open-label, randomized, event-driven study to assess efficacy, safety and pharmacokinetics of macitentan versus standard of care in children with pulmonary arterial hypertension | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2016-003320-23 | Prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study assessing the efficacy and safety of macitentan in Fontan-palliated adult and adolescent subjects. | 2021-07-26 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2016-003653-15 | A multi-center, double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular... | 2021-03-21 | bad-data |
| Reported results | 2016-004035-21 | A multicenter, open-label, single-sequence cross-over study to assess safety, tolerability, and pharmacokinetics of intravenous selexipag in subjects with stable pulmonary arterial hypertension switch... | 2018-05-29 | due-trials |
| Listed as ongoing, but also has a completion date | 2016-004719-10 | Multicenter, non-comparative extension to study AC-058B301, to investigate the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with relapsing multiple sclerosis | 2024-01-16 | bad-data |
| Reported results | 2017-000216-42 | A multi-center, double-blind, placebo-controlled, Phase 3b study in patients with pulmonary arterial hypertension to assess the effect of selexipag on daily life physical activity and patient’s self-r... | 2020-02-10 | due-trials |
| Reported results | 2017-000494-36 | A Phase 2a, multi-center, single-blind, within-subject, placebo-controlled study to assess the pharmacodynamics of ACT-709478 in subjects with photosensitive epilepsy | 2018-04-25 | due-trials |
| Listed as ongoing, but also has a completion date | 2017-003934-10 | mUlticenter, single-arM, open-laBel, long-teRm safety study with macitEntan in patients with puLmonary arterial hypertension previousLy treated with mAcitentan in clinical studies | 2023-12-27 | bad-data |
| Trial is partly outside EEC | 2018-000145-39 | A prospective, multicenter, open-label, single-arm, Phase 2 study to investigate the safety, tolerability and pharmacokinetics of selexipag in children with pulmonary arterial hypertension | bad-data | |
| Reported results Terminated | 2018-001603-37 | A long-term, multicenter, single-arm, open-label extension of the SERENADE study, to assess the safety and efficacy of macitentan in subjects with heart failure with preserved ejection fraction and pu... | 2021-10-12 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-002821-45 | AC-055H302, RUBATO OL, Prospective, multi-center, single-arm, open-label long-term study assessing the safety, tolerability, and effectiveness of macitentan in Fontan-palliated adult and adolescent su... | 2022-01-18 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-002823-41 | A multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential, adaptive, Phase 3 study with open-label extension period to assess the efficacy and safety of selexipag a... | 2022-06-07 | bad-data |
| Listed as ongoing, but also has a completion date | 2018-004887-74 | A Multicenter, Randomized, Double-blind, Placebo-controlled Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag. | 2023-04-19 | bad-data |
| Ongoing | 2019-002533-11 | A Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group, Group-sequential, Adaptive, Event-driven Study to Compare Efficacy, Safety, and Tolerabi... | not-yet-due | |
| Other | 2019-002817-21 | A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel- Group, Event-Driven, Group-Sequential Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Ad... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2019-004131-24 | A prospective, randomized, double-blind, multicenter, placebo-controlled, parallel group, adaptive Phase 3 study with open-label extension to evaluate efficacy and safety of macitentan 75 mg in inoper... | 2023-12-21 | bad-data |
| Listed as ongoing, but also has a completion date | 2019-004783-22 | A PRospective, Multicenter, Single-arm, Open label, Phase 4 Study of the Effects of Selexipag on RighT Ventricular RemOdeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic REsonance ... | 2023-07-28 | bad-data |
| Ongoing | 2020-000475-21 | A Multicenter, Single-arm, Open-label, Long-term Follow-up Safety Study of Selexipag in Participants who Participated in a Previous Selexipag Study. | not-yet-due | |
| Ongoing | 2021-002297-11 | A Prospective, Open-label, Platform Study for Long-term Follow-up of Participants Using Study Intervention in Pulmonary Hypertension Parent Studies | not-yet-due | |
| Trial is outside EEC, and reported results | 2022-002514-16 | A single-arm uncontrolled 12-month Clinical Study to evaluate the Safety and Efficacy of miglustat (Zavesca®) for the Treatment of Niemann-Pick Disease Type C (NPC) in Chinese subjects | bad-data | |
| Listed as ongoing, but also has a completion date | 2022-002754-74 | A multicenter, open-label, single-arm study to assess the pharmacokinetics and safety of macitentan in children aged 1 month to <2 years with pulmonary arterial hypertension | 2024-03-06 | bad-data |